Reply

The authors acknowledged Dr. Montie's review of their reanalysis of the Prostate Cancer Prevention Trial, which highlighted a significant reduction in the risk of prostate cancer with finasteride, specifically a 58% reduction for Gleason score 5, 52% for score 6, and 22% for score 7. They agreed on the importance of these findings and noted the variability in classifying Gleason scores among physicians. The study supported the role of dihydrotestosterone as a risk factor for prostate cancer, emphasizing the clinical and public health significance of finasteride in reducing the risk of these cancers.